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Table
Patients with aGVH Patients without Agvh
Group C1
Cw2,-4,-5,-6,-15
(n9)
Group C2
Cw1,-3-7-8
(n23)
Cw4-Cw4 Cw3-Cw6
Cw4-Cw7 Cw3-Cw12
Cw3-Cw4 Cw3-Cw8
Cw4-Cw7 Cw3-Cw1
Cw4-Cw12 Cw3-Cw7
Cw6-Cw7 Cw3-Cw7
Cw1-Cw6 Cw3-Cw4
Cw2-Cw7 Cw7-Cw4
Cw7-Cw7 Cw4-Cw15
Cw7-Cw8
Cw3-Cw8
Cw3-Cw4
Cw6-Cw7
Cw3-Cw7
Cw6-Cw7
Cw1-Cw7
Cw7-Cw8
Cw3-Cw7
Cw4-Cw6
Cw6-Cw12
Cw3-Cw16
Cw4-Cw12
Cw1-Cw4
Figure. Ofatumumab therapy depletes total CD19+ B cells and IgG. *CD19+ B ce
Abstracts / Biol Blood Marrow Transplant 21 (2015) S322eS354 S343Our objective was to determine the association of poly-
morphisms of HLA-C locus with the risk of developing
aGVHD in pediatric HSCT patients.
All patients who underwent HSCT from an HLA identical
related donor in the period between January 2008 and
September 2013. HLA results that were taken as part of the
protocol for HSCT were analyzed. Descriptive statistics and
the difference between the groups that developed aGVHD
were performed with chi2, and the odds ratio (OR) was
calculated as a measure of association, is also the 95%
calculation.
Nine patients (28.12%) developed aGVHD and 8/9 patients
(88.9%) were carriers of an allele group HLA-C C1 OR 38; 95%
CI 3.7-395; p ¼ 0.0002. Of the 23 patients who did not
develop aGVHD,19 (82.6%) were carriers of at least one allele
of the group C2, RM 0.0263; 95% CI 0.0025 to 0.2735;
p ¼ 0.0002 (table 1).500
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Mofﬁtt Cancer Center and Research Institute, Tampa, FLStandard primary therapy for chronic graft vs. host dis-
ease (GVHD) is incompletely effective. Based on biologic
insights implicating pathogenic B cells, we conducted a
phase I-II trial examining the combination of standard
(1mg/kg/day prednisone) glucocorticoid therapy with
ofatumumab, a humanized anti-CD20 monoclonal anti-
body, for primary chronic GVHD therapy (NCT01680965).
We here report the results of the phase I trial. Patients
age 18 with NIH Consensus moderate-severe chronic
GVHD newly requiring 1mg/kg/day prednisone were
treated at three escalating dose levels (300mg, 700mg,
and 1,000mg) of IV ofatumumab on day 1 and 14 of initial
glucocorticoid therapy. Dose-limiting toxicity (DLT) was
deﬁned by the following: grade 4 infusion reactions,
related grade 4 constitutional symptoms, related grade
3 organ toxicities, and grade 4 neutropenia lasting
>14 days. Secondary endpoints included: adverse events,
infectious complications, clinical response to therapy
including reduction in prednisone dose, and serial mea-
sures of lymphocyte subsets and immunoglobulins. A
total of 12 patients (median age 54, range 25-72) were
treated (dose level 1: n¼3; level 2: n¼3; level 3: n¼6). At
enrollment, overall chronic GVHD was moderate (n¼7) or
severe (n¼5), with diverse organ involvement (skin: n¼8;
mouth: n¼8; eye: n¼8; lung: n¼4; GI: n¼3; liver: n¼5;
genital: n¼2; joint/fascia: n¼5), and both overlap (n¼7)
and classic (n¼5) sub-types were represented. KPS was
 80% in 11/12, median platelet count was 164 (range 92-
287), and median bilirubin 0.6 (range 0.2-0.9). Infusion of
ofatumumab was well tolerated: Two infusion reactions
(grades 2 and 3) occurred, resolved with supportive care,
and all patients completed d1 and 14 infusions. No DLT
was observed. From the total number of adverse events
(n¼27), possibly related AE (n¼3) included grade 1 fa-
tigue, grade 1 transaminitis, and grade 3 hand/foot
cramping. Infectious complications were expected, and
there were no cases of hepatitis B reactivation or pro-
gressive multifocal leukoencephalopathy (PML). At 3
months after therapy initiation, overall clinical response
among evaluable patients was CR (n¼1), PR (n¼7), or SD
(n¼1), and responses were sustained at 6 months
(including one conversion from PR to CR). Encouraging
reduction in prednisone dose was observed at 3 (me-
dian 89%, range 57-100%) and 6 months (median 93%,
range 71-100%). Therapy produced signiﬁcant B-lympho-
penia (ﬁgure). Ofatumumab in combination with predni-
sone is safe, and phase II examination of efﬁcacy is
ongoing.
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Mofﬁtt Cancer Center, Tampa, FLBased on pre-clinical murine and human mechanistic
data, we hypothesized that IL-12/23p40 neutralization
would inhibit pathogenic Th1 and Th17 cells, facili-
tate Treg differentiation, and more effectively prevent
acute graft vs. host disease (GVHD) after allogeneic
hematopoietic cell transplantation (HCT). We conducted a
randomized, double-blind, placebo-controlled trial
comparing ustekinumab (UST)/sirolimus(SIR)/tacrolimus
(TAC) vs. placebo/SIR/TAC (NCT01713400). UST was deliv-
ered (45mg, or 90mg for weight > 100kg) by subcu-
taneous injection on day -1 and day +20. The trial was
powered to detect increase in Treg/total CD4+ in periph-
eral blood at day 30 post-HCT among UST-treated pa-
tients. Secondary biologic studies examined Th1, Th17,
and Treg phenotype and function, and PK/PD measure-
ments. Additional clinical endpoints included engraft-
ment, acute GVHD incidence and associated therapy,
relapse and mortality, and infectious complications.
Adults age  18 with adequate organ function, HCT-CI <
3, and 8/8 (HLA-A, B, C, DRB1) matched sibling or unre-
lated peripheral blood stem cell (PBSC) donors
were randomly assigned 1:1 (UST n¼15, placebo n¼15)
with stratiﬁcation for donor type. Data was un-blinded
after completion of the ﬁnal analysis. There were no sig-
niﬁcant differences in patient, disease, or transplantation
baseline variables between groups; two cases in the UST
group had eDQB1 mismatch vs. none in the placebo
group. Median blood Treg/total CD4+ at day 30 post-HCT
was not different (UST 13, range 2-22; placebo 11, range
3-20), p¼0.41. Median Treg suppressive units at day 30
were comparable: UST 3.51 vs. placebo 2.08, p¼0.7 (ﬁgure
1a). The cumulative incidence of grade II-IV acute GVHD
was similar (ﬁgure 1b), however median time (UST 52
days vs. placebo 29 days, p¼0.017) to acute GVHD onset
was prolonged in UST patients, maximum overall acute
GVHD grade differed, refractory acute GVHD was only
observed in the placebo group, and average prednisone
exposure was reduced in the UST group (ﬁgure 1c). A
greater number of patients in the placebo group experi-
enced death or malignancy relapse (ﬁgure 1d). The
addition of UST to SIR/TAC was safe: In comparison to
placebo/SIR/TAC, there were no signiﬁcant differences in
engraftment, thrombotic microangiopathy, hepatic veno-
occlusive disease, total infection density or occurrence of
CMV, EBV, or HHV-6 reactivation post-HCT. These data
support the safety of this approach, and provide a signal
of clinical efﬁcacy that merits future study. Additional
studies on Th1 and Th17, and PK/PD studies will be
completed for mature presentation at the meeting, and
analysis of allied patient-reported outcome data is under
way.
